MyFinsight
Home
Blog
About
Contact
Download
Download image
Net (decrease)
increase in cash and cash...
-$124M
(-4233.33%↓ Y/Y)
Sales and maturities
of debt securities
$19M
(-83.76%↓ Y/Y)
Sales of equity
securities
$1M
Proceeds from the
issuance of common stock
$2M
(-33.33%↓ Y/Y)
Net income (loss)
$210M
(10400.00%↑ Y/Y)
Other current and
noncurrent assets
-$49M
(87.04%↑ Y/Y)
Other current and
noncurrent liabilities
$41M
(192.86%↑ Y/Y)
Stock-based compensation
expense
$26M
(8.33%↑ Y/Y)
Impairment of tangible and
intangible assets
$19M
(137.50%↑ Y/Y)
Current inventories
-$18M
(-140.00%↓ Y/Y)
Amortization of right-of-use
assets
$10M
Depreciation and
amortization
$10M
(-65.52%↓ Y/Y)
Accounts receivable
-$3M
(-400.00%↓ Y/Y)
Impact from foreign
exchange movements
-$1M
(-150.00%↓ Y/Y)
Net cash (used in)
provided by investing...
-$66M
(-195.65%↓ Y/Y)
Net cash used in
financing activities
-$30M
(70.59%↑ Y/Y)
Net cash (used in)
provided by operating...
-$27M
(-175.00%↓ Y/Y)
Canceled cashflow
$20M
Canceled cashflow
$2M
Canceled cashflow
$387M
Purchases of property and
equipment
$66M
(127.59%↑ Y/Y)
Repayments of debt
$17M
(-92.92%↓ Y/Y)
Cash paid for
repurchases of common stock
$11M
(-93.64%↓ Y/Y)
Settlement of tax on equity
awards
$5M
(-77.27%↓ Y/Y)
Accrued legal and
settlement expenses
-$368M
(4.91%↑ Y/Y)
Purchases of investments
in debt securities
$20M
(17.65%↑ Y/Y)
Deferred income taxes
-$46M
(-866.67%↓ Y/Y)
Back
Back
Cash Flow
source: myfinsight.com
indivior-logo-svg
Indivior Pharmaceuticals, Inc. (INDV)
indivior-logo-svg
Indivior Pharmaceuticals, Inc. (INDV)